Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Amylyx Pharmaceuticals (AMLX) EBITDA (2021 - 2025)

Historic EBITDA for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to -$36.0 million.

  • Amylyx Pharmaceuticals' EBITDA rose 5238.37% to -$36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$157.3 million, marking a year-over-year increase of 4218.44%. This contributed to the annual value of -$314.7 million for FY2024, which is 91112.06% down from last year.
  • Amylyx Pharmaceuticals' EBITDA amounted to -$36.0 million in Q3 2025, which was up 5238.37% from -$42.9 million recorded in Q2 2025.
  • Over the past 5 years, Amylyx Pharmaceuticals' EBITDA peaked at $20.2 million during Q2 2023, and registered a low of -$122.1 million during Q1 2024.
  • Moreover, its 5-year median value for EBITDA was -$37.8 million (2025), whereas its average is -$35.6 million.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' EBITDA soared by 13723.48% in 2023 and then tumbled by 584885.53% in 2024.
  • Amylyx Pharmaceuticals' EBITDA (Quarter) stood at -$28.3 million in 2021, then crashed by 57.49% to -$44.6 million in 2022, then surged by 104.34% to $1.9 million in 2023, then tumbled by 2202.07% to -$40.7 million in 2024, then increased by 11.38% to -$36.0 million in 2025.
  • Its EBITDA was -$36.0 million in Q3 2025, compared to -$42.9 million in Q2 2025 and -$37.8 million in Q1 2025.